AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
April 15 2024 - 8:55AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM”) today announced that Charles Lapp, MD,
is joining the company to help lead its efforts to develop Ampligen
(rintatolimod) as a potential treatment for Myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.
Dr. Lapp has played a key role in AIM’s
long-standing AMP-511 Expanded Access Program for the treatment of
ME/CFS and Long COVID, having founded one of the clinical trial’s
key sites, the Hunter-Hopkins Center in Charlotte, N.C., from which
he recently retired. As a Consulting Medical Officer and an
independent contractor, he will help manage the company’s research
programs related to ME/CFS and Long COVID, including the
development of protocols and new clinical trials.
Dr. Lapp states: “I’m eager and excited for the
opportunity to continue working with Ampligen. Ampligen is the only
treatment for people with ME/CFS that has shown efficacy in
clinical trials and I believe this will be confirmed in further
trials requested by the FDA in ME/CFS and also potential further
trials in Long COVID. I am devoted to doing whatever I can to get
Ampligen FDA-approved and available for commercial use.”
Dr. Lapp is a graduate of Albany Medical
College. He has been the medical advisor to the Chronic Fatigue
Syndrome Association of America, the American Fibromyalgia Syndrome
Association, and the National Fibromyalgia Association; and a board
member of the International Association for CFS and FM.
AIM Chief Executive Officer Thomas K. Equels
states: “Having worked with Dr. Lapp for many years, I’m
continually impressed by his knowledge, confidence and experience.
He is one of the foremost experts in his field and we are extremely
grateful that he is joining the AIM team.”
For more information about AIM’s ongoing work
with COVID-19-related conditions, see the recent announcement: AIM
ImmunoTech Reports Positive Topline Results from Phase 2 Study
Evaluating Ampligen® for the Treatment of Post-COVID
Conditions.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLCJenene Thomas(833) 475-8247AIM@jtcir.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/635c0bae-2a83-41c3-a149-9169f978f583
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2024 to May 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2023 to May 2024